NPFR receptor ligand

NPY2R - Drugs, Indications, Patents - Synapse

nortrachelogenin cas no 34444 37 6 powder macro

NPY2R

Last update 08 May 2025

Basic Info

Synonyms

Neuropeptide Y receptor type 2, neuropeptide Y receptor Y2, NPY-Y2 receptor

Introduction

Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY > NPY > PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu-31, Pro-34] NPY > PP, [Pro-34] PYY and NPY free acid.

24 Drugs associated with NPY2R

Drug	Target	Mechanism	Active Org.	Originator Org.	Active Indication	Drug Highest Phase
NNC-0165-1875	NPY2R	NPY2R agonists	Novo Nordisk A/S	Novo Nordisk A/S	Obesity	Phase 2
CIN-110	NPY2R	NPY2R agonists	CinFina Pharma	CinFina Pharma	Obesity	Phase 1
BI-1820237	NPY2R	NPY2R agonists	Gubra A/S	Boehringer Ingelheim International GmbH	Obesity	Phase 1

Clinical Trials

12 Clinical Trials associated with NPY2R

NCT06352424 / Completed Phase 1 - A Single-dose, Randomized, Placebo-controlled Phase I Study on the Effects of a Subcutaneous Dose of BI 1820237 and BI 456906, and Combination Thereof on Functional MRI Measurements in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Single-blind, Cross-over Design). Start Date 30 Apr 2024. Sponsor / Collaborator: Boehringer Ingelheim GmbH.
NCT05751226 / Completed Phase 1 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Different Titration Schedules of Subcutaneous Doses of BI 1820237 Alone or Together With Either Semaglutide or BI 456906 in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Multiple Dose, Single-blind, Randomised, Placebo-controlled, Parallel Group Design). Start Date 11 Apr 2023. Sponsor / Collaborator: Boehringer Ingelheim GmbH.
NCT05110664 / Unknown status Not Applicable IIT - A Double-blind, Cross-over, Placebo-controlled, Proof-of-concept Study Using Oral Peptide YY3-36 Solution to Investigate the Mechanistic Role of Lingual PYY in Regulating Appetite, Energy Intake and Food Preference in People With Overweight/Obesity. Start Date 01 Feb 2022. Sponsor / Collaborator: University College London.

Research and News

Literatures

646 Literatures (Medical) associated with NPY2R

01 Apr 2025, Current Opinion in Neurology: State-of-the-art gene therapy in epilepsy. Review. Author: Walker, Matthew C.
01 Apr 2025, European Journal of Medicinal Chemistry: Rational design of dual-agonist peptides targeting GLP-1 and NPY2 receptors for regulating glucose homeostasis and body weight with minimal nausea and emesis. Article. Author: Tang, Chunli et al.
26 Mar 2025, Science Translational Medicine: Variant screening of PYY 3–36 leads to potent long-acting PYY analogs with superior Y 2 receptor selectivity. Article. Author: Jessen, Carsten et al.

News

7 News (Medical) associated with NPY2R

04 Nov 2024, pipelinereview.com: CinFina Pharma Presents Positive Phase 1 Study Results in Poster Session for CIN-109 and in Late-Breaking Poster for CIN-110, Demonstrating the Potential of Next-Generation Mechanisms at ObesityWeek® 2024. CIN-110 was well-tolerated and demonstrated noteworthy decreases in caloric intake and weight compared to placebo based on topline interim data from Phase 1 single ascending dose (SAD) study. CIN-109 produced meaningful weight loss.